Clinical Trial: XP-005 Personalized Vaccine Alone or in Combination With Toripalimab for the Prevention of Relapse After Remission in Acute Myeloid Leukemia

U.S., May 21 -- ClinicalTrials.gov registry received information related to the study (NCT06980155) titled 'XP-005 Personalized Vaccine Alone or in Combination With Toripalimab for the Prevention of Relapse After Remission in Acute Myeloid Leukemia' on May 12.

Brief Summary: The main objective of this study is to observe and evaluate the safety and tolerability of the XP-005 personalized tumor mRNA vaccine, either alone or in combination with toripalimab, for the treatment of acute myeloid leukemia patients who are in remission with minimal residual disease (MRD) positive but cannot undergo allogeneic hematopoietic stem cell transplantation.

Study Start Date: May 30

Study Type: INTERVENTIONAL

Condition: Acute Myeloid Leukemia

Interven...